What's new?

Paris, France, July 10th. 2018. Sofinnova Partners, a leading venture capital firm specialized in Life Sciences, today announced that Otsuka Holdings is acquiring its portfolio company ReCor Medical, a medical device company specialized in the treatment of hypertension. The terms of the acquisition are being withheld due to non-disclosure obligations.

ReCor Medical was created in 2009 by Sofinnova Partners, Mano Iyer – who was then entrepreneur-in-residence at Sofinnova Partners and now Chief Operating Officer of ReCor – and Professor Jacques Seguin, MD, who became a large private investor in ReCor. Prof. Seguin was previously founder and CEO of CoreValve, a past Sofinnova portfolio company and a leader in the transcatheter valve replacement space, which was sold to Medtronic. Sofinnova Partners was the sole venture capital investor in ReCor Medical and remained its largest shareholder until the sale to Otsuka.

ReCor Medical is an innovative medical device company that developed the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. ReCor recently announced positive results of its landmark RADIANCE-HTN SOLO hypertension study at EuroPCR 2018.

Antoine Papiernik, Managing Partner at Sofinnova Partners and ReCor Board Member, said: “ReCor perfectly illustrates our investment strategy: we worked hand-in-hand with Mano Iyer to create the business vision and plan for ReCor. We then founded and funded the company, and opened our network of experts, key opinion leaders and board members to help grow it. We brought trusted entrepreneurs Jay Watkins as Chairman and Andy Weiss as CEO to help guide and operate the company through to a corporate transaction to our partner Otsuka.”

Jay Watkins, Chairman of ReCor Medical said: “Sofinnova Partners remains one of few VCs willing to fund early-stage med-tech ventures targeting large and important new markets. The firm played a critical role throughout ReCor’s life, and has proven to be a reliable, value-added partner for the company. The field of renal denervation has been a complex one over the last few years with periods of euphoria and periods of doubt. Sofinnova Partners’ support remained constant throughout, helping to build a strong partnership with Otsuka and then navigate through the challenges to a very successful trade sale.”

Mano Iyer, Founder and COO of ReCor Medical added: “ReCor is a success story because Sofinnova Partners, consistent with its philosophy, saw the value of an opportunity which did not yet exist. It had the vision to create and fund the company, not only in the very beginning, but also during the critical early years. Despite the dramatic swings in the field, Sofinnova Partners’ confidence in me and in the management team was essential to keep us motivated when others lost hope. This great exit is therefore particularly sweet.”

Andrew M. Weiss, CEO of ReCor Medical adds: “I came to ReCor thanks to Antoine Papiernik’s introduction to the company. With his help, our team developed the partnership with Otsuka and was able to remain focused on value creation. The recent announcement of our positive RADIANCE-HTN SOLO study results and now the merger with Otsuka demonstrate that our teamwork with Sofinnova Partners was successful. We now have an opportunity to transform the treatment of hypertension and benefit millions of potential patients while providing a solid return for our investors. I look forward to continuing to work to make this technology a possible standard of care in hypertension treatment”.

For more information, please contact:
International: Anne Rein
Tel: +33 6 03 35 92 05
e-mail: anne.rein@strategiesimage.com
United States: Kate Barrette
Tel: +1 212 223 0561
e-mail: kbarrette@rooneyco.com

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead or cornerstone investor in seed, start-ups, corporate spin-offs and late stage companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.9 billion under management. For more information: www.sofinnova.fr

About ReCor Medical, Inc.
ReCor Medical is a medical device company that designs and manufactures the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. The Paradise System is approved for sale in the EU and bears a CE mark, but is not approved for sale in the United States. The System’s intravascular catheters denervate renal nerves by combining the protection of water-based cooling of the renal artery with high intensity ultrasound energy for circumferential renal nerve ablation. The Paradise System has been studied in clinical trials of approximately 300 patients to date. Following the positive outcomes of the RADIANCE-HTN SOLO trial, ReCor will continue its evaluations of Paradise in RADIANCE-HTN TRIO (a feasibility study of patients with resistant hypertension) and REQUIRE (a pivotal study of patients with resistant hypertension in Japan and Korea), and launch the RADIANCE II pivotal study (a study of patients with moderate hypertension) in the United States and Europe.

About Otsuka Holdings Co., Ltd. and Otsuka Medical Devices Co., Ltd.
Otsuka Holdings Co., Ltd. is the holding company of the Otsuka group, a global healthcare group headquartered in Tokyo, Japan. With operations in pharmaceuticals, nutraceuticals, medical devices and other health-related businesses, the group generated worldwide sales of JPY1,240 billion in the fiscal year ended December 2017.

Established in 2011, Otsuka Medical Devices Co., Ltd. is a fully-owned subsidiary of Otsuka Holdings and one of its core operating subsidiaries. Otsuka Medical Devices focuses on the development and commercialization of endovascular devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment.
Otsuka Medical Devices conducts the REQUIRE trial for renal denervation in hypertensive patients (n=140), who are uncontrolled on 3 or more medications including a diuretic, in Japan and Korea through its subsidiary JIMRO Co., Ltd.


esmertec and Insignia collaborate to deliver Over-the-Air Repair™ capabilities for mobile terminals

Zurich, Switzerland, February 11, 2003 * * *
esmertec AG, the leading global supplier of embedded Java? virtual machines (JVMs) for the mobile world, and Insignia Solutions today announced an agreement whereby esmertec acquires the Insignia JVM related assets with the exception of Jeode Intellectual Property. esmertec will assume the entire JVM business through a final asset purchase in June 2004. esmertec and Insignia will also work together to proliferate Insignia’s Secure System Provisioning technology to esmertec’s customers and markets. Insignia Solutions is a market-share leading supplier of JVM software solutions for high-growth markets including mobile, digital TV, telematics and embedded systems and has partnerships with many key industry players. This acquisition strengthens and consolidates esmertec’s leadership position in providing Java solutions for mass market mobile and embedded devices. Combining the esmertec and Insignia customer bases as well as best-in-class compiling technologies provides the mobile industry with a best-of-breed solution.

” This acquisition makes perfect sense from a number of perspectives”, said Alain Blancquart, CEO of esmertec. “The combined R&D team will be the largest and most experienced in the industry, allowing us to continue to deliver world-class solutions to our partners and customers”. “In addition to this we will be able to extend esmertec’s market reach by building on the strong position that Insignia has in the PDA, industrial and automotive markets. I am truly delighted by this deal and am excited about the future”, he concluded. Commenting on the complimentary compiling technologies of the two companies, Hansruedi Heeb, esmertec’s President and CTO, said: “We are excited by the prospect of combining the brainpower of the two leading engineering teams in compiling J2ME CLDC solutions and we look forward to strengthening our leadership in the entire embedded Java space thanks to Insignia’s outstanding and proven technology”. With the sale of Insignia’s JVM business to esmertec, Insignia is refocusing on its highly successful Secure System Provisioning product line. The two companies have agreed to work together to deliver an end-to-end Over-the-Air Repair solution leveraging the complimentary strengths of the two companies. In addition, Insignia will gain a highly leverage entry into esmertec’s customer base and markets with this solution. “We are delighted to have reached an agreement with esmertec”, said Mark McMillan, President and COO of Insignia. “This acquisition makes esmertec the leading worldwide provider of mobile services enabling software in the industry and the infusion of cash to Insignia enables us to exclusively focus on the significant market opportunity for Secure System Provisioning – it’s a win-win situation for both companies”.

About esmertec
esmertec is the leading software company focusing on Java™ and mobile software technologies for handheld systems. Considered to be one of the most important players in the independent VM supplier space, its flagship product, Jbed™ ME, certified by Sun Microsystems, delivers high performance computing on small devices to service providers, mobile device manufacturers and application developers. Founded in 1999, esmertec is based in Switzerland with sales, engineering and support offices in the United States and Singapore and representation in Japan.

About Insignia Solutions
Insignia Solutions’ provisioning-infrastructure software enables wireless carriers and mobile device manufacturers to fully capitalize on the mobile service opportunity. Founded in 1986, Insignia is a market-share leading supplier of Java virtual machine software solutions for high-growth markets including mobile, digital TV, telematics, and embedded systems. More than 40 million units of Insignia’s JVM™ technology are licensed by major partners including Samsung, HP/Compaq, BSQUARE, Wind River, Fujitsu, NEC, Toshiba, Motorola and Siemens AG. Insignia Solutions is traded on NASDAQ under the symbol INSG. The company is headquartered in Fremont, California with R&D and European operations based in the United Kingdom, and its Asian HQ in Japan. For additional information about Insignia or its products please visit http://www.insignia.com/.

Visit website http://www.esmertec.com


Paris, 13 December 2002. Sofinnova Partners announces the departure of Franck Delorme, General Partner responsible for developing the Information Technology sector alongside Olivier Protard. This move will not change the firm’s investment strategy, which is to focus on two key sectors: Information Technology and Life Sciences. The hiring of Alain Rodermann, Partner, in 1999 and the additions to the IT team over the last two years of a new Partner, Jean Schmitt, and two new Investment Associates, gives Sofinnova Partners the means to continue developing this sector.

” After twelve years of operational and international management experience with Dassault Systèmes, I joined Sofinnova Partners as General Partner in 1995. I have been with the firm for eight years, which corresponds to two investment cycles in this business. I now want to capitalize on these two types of experience, and focus on operational management with a strong entrepreneurial outlook”, said Franck Delorme.

Olivier Protard added: “This is a natural career move for Franck and we wish him well. Furthermore, while this decision was motivated by personal projects, it was a mutual agreement, within the partnership spirit that guides the entire team”.

During his eight years with Sofinnova Partners, Franck Delorme made twelve investments in both software and networking/telecom companies. Examples are Activia Networks, MaxiMiles, Ortems, Sefas, Solsoft, Staff & Line and, more recently, CTS and 6Wind.

About Sofinnova Partners
Based in Paris since 1972, Sofinnova Partners is a leading independent French and European venture capital firm. With key operations in the information technology and life science sectors, its investment strategy is based on two principles: “Invest in projects with a high potential in their early stages of development” and “Act as lead or co-lead investor”. Its investment team comprises 13 investment partners who are all experts in their field and can assist companies in which Sofinnova chooses to invest. Sofinnova Partners has more than 500 million euros under management, a loyal base of international investors, and plans to strongly reinforce its European development in the coming years.


Ghent, Belgium, 25 September 2002 – Ablynx nv today announced that it has completed a 5 million euro venture financing round. Investors are GIMV (Belgium), Sofinnova Partners (France), and Gilde Investment Management (the Netherlands). The recently founded biopharmaceutical company will develop and commercialize a novel class of single-domain antibodies for health care applications, with a primary focus on therapeutics. Ablynx, headquartered in Ghent, is a spin-off of VIB (Flanders Interuniversity Institute for Biotechnology, Belgium) and VUB (Free University of Brussels, Belgium).

The “Ablynx antibodies” are derived from single-domain antibodies that naturally occur in certain animal species belonging to the Camelidae (camel, dromedary and llama), and that were initially discovered by researchers at the Free University of Brussels. Additional research conducted over the last few years by a multidisciplinary team within the Flanders Interuniversity Institute for Biotechnology (VIB), revealed that this novel class of antibodies exhibits some unique advantages over conventional multi-domain antibodies for use as pharmaceutical drugs. This extensive effort resulted in the creation of a broad knowledge base and an impressive intellectual property (IP) estate comprising over 40 patents and patent applications. Ablynx has obtained exclusive rights to this knowledge and IP for the field of human and animal health care, including proteomics applications.

Ablynx’ antibodies are engineered in such a way that they contain a single antigen-binding domain and are only one tenth the size of a conventional antibody. Because of their small size, they can penetrate more effectively into organs or tissues upon administration as therapeutic drugs. Moreover, Ablynx antibodies are able to bind to epitopes that are not (or only rarely) accessible to conventional antibodies, such as active site cavities in enzymes. They also bind with high specificity and affinity to a broad spectrum of potential disease targets and exhibit superior solubility and stability, even resisting the action of gut proteases. Their simple structure allows them to be efficiently produced through microbial fermentation, permitting cost-effective production on a large scale. Ablynx believes that these unique features will enable the Company to rapidly develop proprietary drugs with improved characteristics to compete effectively in the growing market of antibody-based therapeutics.

Dr. Mark Vaeck has recently joined Ablynx as Chief Executive Officer. Dr. Vaeck has worked in the biotechnology and pharmaceutical industry since 1983. Before joining Ablynx, he was Chief Operating Officer of Ceres Inc., a plant genomics company based in Malibu, California. Prior to that, he held senior management positions at Keygene, EuroCetus (Chiron Corp.), UCB Pharma, and Plant Genetic Systems. Dr. Vaeck received his Ph.D. in Immunology from the Free University of Brussels.


Ablynx’ first-round financing of EUR 5 million was provided by an international consortium of reputed venture capital companies with a known track record in biotech financing: GIMV-Biotech Fund Flanders (Belgium), Sofinnova Partners (France), and Gilde (the Netherlands). The Company is headquartered in Ghent and has research collaborations with VIB and VUB. Ablynx currently employs 10 people and intends to grow to about 50 within the next two years.

For more information about Ablynx:
Mark Vaeck, CEO, mark.vaeck@ablynx.com

Visit website http://www.ablynx.com


La société suisse Addex Pharmaceuticals annonce aujourd’hui la clôture d’un premier tour de table de 10 M€ (CHF 15.75 million ) mené conjointement par Index Ventures et Sofinnova Partners. Techno Venture Management, BCV Initiative Capital ainsi que des investisseurs individuels ont aussi participé à ce tour de financement. Richard Rimer, Partenaire chez Index Ventures et Antoine Papiernik, Partenaire Associé chez Sofinnova Partners, rejoignent le Conseil d’administration de la société aux côtés d’autres personnalités expérimentées du monde de l’industrie pharmaceutique et des biotechnologies.

Addex Pharmaceuticals (www.addexpharma.com) est une société de biopharmacie spécialisée dans la découverte, le développement et la mise sur le marché de nouveaux produits thérapeutiques pour le traitement des dépendances et d’autres états neuropsychiatriques. Addex Pharmaceuticals utilise une nouvelle approche scientifique intégrant les technologies moléculaires, behavioristes et chimiques afin de combattre la dépendance à la drogue. “La dépendance, qui fait partie des grandes questions de santé publique, représente un marché très étendu encore peu exploré. Addex Pharmaceuticals vise ce marché et plus particulièrement les dépendances à la nicotine, à l’alcool, à la cocaïne et aux opiacés”, souligne François Conquet, Président-directeur général d’Addex Pharmaceuticals. “Nous projetons aussi d’explorer d’autres indications telles que les processus de dépendance générée par l’anxiété et la dépression.”

L’équipe de recherche d’Addex Pharmaceuticals bénéficie à la fois d’une expertise dans le domaine de la dépendance et dans celui du développement pharmaceutique. Les membres de cette équipe se connaissent et travaillent ensemble depuis de nombreuses années. Il s’agit de scientifiques aux compétences complémentaires qui ont une connaissance en profondeur de l’industrie pharmaceutique. François Conquet en est le Président-directeur général, Mark Epping-Jordan, le Directeur Scientifique, Timothy Dyer, le Directeur Financier et Vincent Mutel, le Directeur de la Recherche et du Développement. George Koob, du Scripps Research Institute, Mark Geyer de l’Université de Californie (San Diego), Pierre Magistretti de l’Université de Lausanne, Barbara Mason de l’Université de Miami, et Charles Grudzinskas du CDDS (Université de Georgetown) font partie du Conseil Scientifique. “La valeur de cette équipe et son expertise tant industrielle que scientifique dans ce domaine bien spécifique, auront un impact certain sur le traitement de la dépendance,” commente Antoine Papiernik, Partenaire Associé chez Sofinnova Partners.

La plate-forme intégrée de découverte de médicaments développée par la société lui donne la possibilité d’identifier de nouvelles cibles et de découvrir des produits innovants pour le traitement de la dépendance. Parallèlement au développement de ses propres produits, Addex Pharmaceuticals a pour stratégie de prendre en licence des produits candidats à différents stades de leur développement, et notamment des produits en phase d’essais cliniques. “L’approche d’Addex Pharmaceuticals en termes de traitement de la dépendance est la seule à couvrir l’ensemble de la chaîne allant de la découverte scientifique au développement du produit et à sa mise sur le marché”, a déclaré Richard Rimer, Partenaire d’Index Ventures.

Les mécanismes de la dépendance à la drogue sont complexes : ils entraînent des altérations dans les processus naturels de la connaissance, de l’affect et des éléments vitaux constituant l’intégrité de l’espèce – la nourriture, l’eau, le sexe et l’instinct maternel -. Les médicaments visés devraient entraîner une réduction, voire une suppression de l’usage de la drogue, prévenir les rechutes chez les patients, atténuer leur état de manque et réduire l’impact pathologique et/ ou le taux de mortalité. La plupart des thérapies actuelles agissent sur les mêmes cibles que les drogues elles-même. Cependant, parce que ces cibles stimulent les quatre éléments vitaux précités, ainsi que des processus fondamentaux, comme l’activité motrice, leur modulation provoque fréquemment des effets secondaires significatifs. Contrairement aux thérapies existantes, la stratégie de développement d’Addex vise des cibles situées en amont du processus de dépendance et inhibe donc totalement cette dépendance. Les produits d’Addex Pharmaceuticals devraient donc s’appliquer à un plus grand nombre de dépendances, tout en évitant les effets secondaires habituellement observés. Cette approche pourrait également permettre le développement de médicaments efficaces pour le traitement d’autres indications psychiatriques.

A propos d’Addex Pharmaceuticals
Addex Pharmaceuticals (www.addexpharma.com) est une société de biopharmacie suisse qui utilise une nouvelle approche scientifique intégrant à la fois les technologies moléculaires, behavioristes et chimiques permettant de combattre la dépendance à la drogue et d’autres maladies neuropsychiatriques. Addex Pharmaceuticals s’appuie sur sa plate-forme intégrée de découverte de médicaments pour identifier de nouvelles cibles et développer des produits innovants pour le traitement de la dépendance. Parallèlement au développement de ses propres produits, Addex Pharmaceuticals cherche à prendre en licence des produits candidats à différents stades de développement, notamment des produits déjà en essais cliniques pour le traitement de la dépendance.

A propos d’Index Ventures
Index Ventures est une société de capital-risque européenne qui gère plus de 500 millions de dollars de fonds, spécialisée dans les hautes technologies et les sciences de la vie. Index, qui a initié ses investissements dans la technologie européenne en 1992, a financé plus de 40 sociétés au cours des dernières années. Index travaille en étroite collaboration avec les entrepreneurs afin de développer des sociétés capables de devenir des leaders dans leur domaine. Parmi les investisseurs d’Index Ventures, on compte plusieurs sociétés de technologie de premier plan ainsi que des investisseurs institutionnels. Index a en particulier investi dans des sociétés spécialisées dans les sciences de la vie, comme Genmab (Cotée au Neuer Markt: 565132.F, à Copenhagen: GEN.CO), Cellzome, 7TM Pharma, BioXell et ParAllele Bioscience. Pour plus d’informations : http://www.indexventures.com.

A propos de Sofinnova Partners
Basée à Paris depuis 1972, Sofinnova Partners est l’une des sociétés de capital-risque leaders en Europe, spécialisée dans le financement et l’accompagnement de jeunes sociétés européennes et américaines en forte croissance, dans les secteurs des technologies de l’information et des sciences de la vie. Sofinnova Partners gère au total plus de 500 M € de fonds. Dans les cinq dernières années, Sofinnova Partners a réalisé plus de 60 investissements, principalement en tant que chef de file. Dans le secteur des sciences de la vie, ces investissements se sont concentrés sur des sociétés de biopharmacie ou d’instrumentation médicale telles que Actelion, Nicox, Novuspharma, IDM et SpineVision.

Visit website http://www.addexpharma.com


Esmertec, société suisse créée en 1999 et leader mondial dans la conception, l’édition et la diffusion de Java™ Virtual Machines (JVM) embarquées sur les téléphones mobiles (http://www.esmertec.com/), vient de clôturer un second tour de table d’un montant de 10 M€.

Sofinnova Partners, leader de ce tour de financement, a investi 4M€ aux côtés d’Earlybird (Allemagne) et de Partners Group (Suisse). Jean Schmitt, Partner de Sofinnova Partners, rejoint le Conseil d’Administration de la société, où il apportera son expertise du marché international des télécoms en tant qu’ancien dirigeant fondateur de SLP Software (société spécialisée dans les logiciels de CRM destinés aux opérateurs télécoms, acquise par Gemplus).

Les JVM embarquées sur les téléphones mobiles vont permettre aux opérateurs télécoms de déployer des applications à valeur ajoutée (utilitaires, jeux, applications business) sur des parcs hétérogènes de terminaux mobiles. En Corée, ces nouvelles applications sur les téléphones mobiles ont déjà fait progresser l’ARPU (revenu moyen par utilisateur) de 76% dans les 6 derniers mois (1) .

Plus petite et dix fois plus rapide que celle de ses concurrents, la JVM d’Esmertec permet d’exécuter des logiciels Java™ sophistiqués, d’allonger la durée de vie des batteries de téléphones et de diminuer le coût du hardware. Les premiers terminaux équipés de JVM commenceront à être distribués en masse en Europe dès le troisième trimestre 2002.

“Cet investissement s’inscrit parfaitement dans la stratégie de Sofinnova Partners dans la téléphonie mobile, où nous privilégions certains marchés émergents tels que la facturation de contenu (Volubill) ou les JVM embarquées (Esmertec)”, a déclaré Jean Schmitt. “En 2003, les prévisions indiquent que 667 millions de nouveaux téléphones mobiles seront vendus dans le monde (2). 25% d’entre eux seront équipés de JVM. Grâce à la supériorité technologique de ses JVM, Esmertec est très bien positionnée sur ce marché émergent en pleine croissance.”

Visit website http://www.esmertec.com


Sofinnova Partners has led investments totalling €5.4M in the first rounds of two new biotech start-ups, Faust Pharmaceuticals and Carex, after having contributed to their formation. Out of these €5.4M, €2M go to Faust Pharmaceuticals, a company created out of the CNRS campus in Gif sur Yvette, and specialised in the development of drugs to treat diseases of the central nervous system, and €3.3M to Carex, a spin off of the Institute of Genetics and Molecular and Cellular Biology based in Illkirch, focused on the development of new treatments for metabolic diseases.

To complete these two financings, Sofinnova Partners has invited some of its European financial partners: Auriga Partners, a French venture capital company, for Faust Pharmaceuticals (€1M) ; Gimv (€2M) and Mara Ventures (€0,7M), two Belgian investors, for Carex.

These two financings, managed by Bernard Gilly, Partner at Sofinnova Partners, are good examples of the venture capital firm’s investment strategy, which concentrates on “hybrid” business models associating a technology platform and a portfolio of pharmaceutical products under development, in major therapeutic areas of clear unmet clinical needs such as pathologies of the Central Nervous System, cancer, infectious and metabolic diseases, as well as on medical instruments.

With the directly operational involvement of Bernard Gilly in Faust Pharmaceuticals and Carex, Sofinnova Partners has played a leading role, alongside the scientific founders, in putting in place the structure of the two companies, providing with the seed financing as well as recruiting the management teams.

Faust Pharmaceuticals and Carex have therefore had the opportunity to benefit from the start of the managerial experience of Bernard Gilly, previously CEO of Transgène (a company which he took public in 1998 on the Paris Nouveau Marché and on Nasdaq), and prior to that head of the R&D at Pasteur Mérieux and then Biomérieux.

” These two new investments illustrate perfectly Sofinnova Partners’ very early involvement in our companies “, declares Antoine Papiernik, General Partner at Sofinnova Partners. ” Sofinnova Partners has demonstrated this approach several times in the past by recruiting ” entrepreneurs in residence “, as in Neuro3D, or by putting in place temporary management, as in the early days of Diatos or Neurotech. With this experience of ” Acting CEO “, Bernard Gilly goes even further in helping our companies off the ground. “


Sofinnova Partners investit 5,4 M € en tant que chef de file dans les premiers tours de table de deux nouvelles sociétés de biotechnologie, Faust Pharmaceuticals et Carex, qu’il a contribué à créer. Sur ces 5,4 M €, 2 M € vont à Faust Pharmaceuticals, société émanant du campus de recherche du CNRS de Gif-sur-Yvette et spécialisée dans le développement de médicaments destinés au traitement des maladies du système nerveux central, et 3,3 M € à CareX, spin-off de l’Institut de Génétique et Biologie Moléculaire et Cellulaire d’Illkirch, orientée vers le développement de nouveaux traitements des maladies métaboliques.

Sofinnova Partners a invité, pour compléter ces tours de table, quelques-uns de ses partenaires financiers européens : Auriga Partners, société de capital risque française, pour Faust Pharmaceuticals (1 M €) ; GIMV (2 M €) et Mara Ventures (0,7 M €), deux fonds belges, pour Carex.

Ces deux opérations, réalisées par Bernard Gilly, Partenaire de Sofinnova Partners, s’inscrivent dans la stratégie d’investissement de Sofinnova Partners qui privilégie aujourd’hui les ” business models hybrides ” (plate-forme technologique associée à un portefeuille de produits en développement) dans des domaines thérapeutiques porteurs au sens des besoins médicaux non satisfaits (pathologies du Système Nerveux Central (SNC), cancer, maladies infectieuses et métaboliques) ainsi que l’instrumentation médicale.

Avec la participation très opérationnelle de Bernard Gilly dans Faust Pharmaceuticals et Carex, Sofinnova Partners est intervenu directement, aux côtés des fondateurs scientifiques, pour mettre en place la structure des deux sociétés, assurer leur financement d’amorçage ainsi que le recrutement des équipes de management.

Faust Pharmaceuticals et Carex ont ainsi pu bénéficier dès leur démarrage de l’expérience managériale de Bernard Gilly ( ancien Directeur Général de Transgène qu’il a introduit en 1998 sur le Nouveau Marché de Paris et au Nasdaq ; il a également dirigé la R&D de Pasteur Mérieux puis de bioMérieux).

” Ces deux nouveaux investissements illustrent l’implication très en amont de Sofinnova Partners dans ses participations “, a déclaré Antoine Papiernik, Partenaire Associé de Sofinnova Partners. ” Sofinnova Partners a déjà, à plusieurs reprises, procédé au recrutement d’ ” entrepreneurs en résidence ” (Neuro3D), ou à la mise en place d’équipes de management temporaires (Neurotech, Diatos). Avec cette expérience d’ ” Acting CEO “, Bernard Gilly pousse encore plus loin cette approche d’accompagnement à la création de nos sociétés “.